{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:46:17Z","timestamp":1794501977642,"version":"4.9.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.03.042","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T17:43:37Z","timestamp":1776015817000},"page":"960.e1-960.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Maintenance Treatment With Gilteritinib Suppresses Post-transplant Relapse in Relapse\/Refractory FLT3-Mutated Acute Myeloid Leukemia"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-5093","authenticated-orcid":false,"given":"Yasuyuki","family":"Arai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3522-2278","authenticated-orcid":false,"given":"Marie","family":"Ohbiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mio","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8814-230X","authenticated-orcid":false,"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0945-0513","authenticated-orcid":false,"given":"Kazunori","family":"Imada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5054-9104","authenticated-orcid":false,"given":"Yuta","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-3179","authenticated-orcid":false,"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-9307","authenticated-orcid":false,"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamiko","family":"Sakata-Yanagimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Hiramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7322-5460","authenticated-orcid":false,"given":"Noboru","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5650-1752","authenticated-orcid":false,"given":"Hiroki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Uno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-271X","authenticated-orcid":false,"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1822-9976","authenticated-orcid":false,"given":"Akiyoshi","family":"Takami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1953-8463","authenticated-orcid":false,"given":"Takaaki","family":"Konuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1602-9775","authenticated-orcid":false,"given":"Masamitsu","family":"Yanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.03.042_bib0001","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/asheducation-2006.1.178","article-title":"FLT3 mutations: biology and treatment","author":"Small","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.jtct.2026.03.042_bib0002","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.jtct.2026.03.042_bib0003","first-page":"7233","article-title":"Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study","volume":"61","author":"Whitman","year":"2001","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.jtct.2026.03.042_bib0004","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.042_bib0005","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/jjco\/hyac069","article-title":"Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed\/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan","volume":"52","author":"Sugamori","year":"2022","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.03.042_bib0006","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/bloodadvances.2019000174","article-title":"Gilteritinib: potent targeting of FLT3 mutations in AML","volume":"4","author":"Levis","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.042_bib0007","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12185-024-03730-2","article-title":"JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1. Acute myeloid leukemia (AML)","volume":"119","author":"Maeda","year":"2024","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.042_bib0008","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1586\/ehm.10.32","article-title":"Relapse after allogeneic stem cell transplantation","volume":"3","author":"Barrett","year":"2010","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.042_bib0009","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a Center for International Blood and Marrow Transplant Research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.042_bib0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.042_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.12.006","article-title":"Outcomes in patients with FLT3-mutated relapsed\/refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL Trial of gilteritinib versus salvage chemotherapy","volume":"29","author":"Perl","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"19","key":"10.1016\/j.jtct.2026.03.042_bib0012","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1002\/cncr.30140","article-title":"Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis","volume":"122","author":"Deol","year":"2016","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.042_bib0013","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2011.36.9868","article-title":"Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis","volume":"30","author":"Brunet","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.03.042_bib0014","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2016.01.013","article-title":"Allogeneic hematopoietic stem cell transplantation in FLT3-ITD-positive acute myelogenous leukemia: the role for FLT3 tyrosine kinase inhibitors post-transplantation","volume":"22","author":"Schiller","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.03.042_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.08.008","article-title":"Efficacy of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia: results of a systematic review and meta-analysis","volume":"28","author":"Kharfan-Dabaja","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2026.03.042_bib0016","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41409-022-01619-4","article-title":"Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation","volume":"57","author":"Zhang","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"10.1016\/j.jtct.2026.03.042_bib0017","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.042_bib0018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","article-title":"Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)","volume":"103","author":"Atsuta","year":"2016","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.042_bib0019","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12185-015-1907-9","article-title":"Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation","volume":"103","author":"Kanda","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2026.03.042_bib0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-015-0201-x","article-title":"Clinical significance of high-dose cytarabine added to cyclophosphamide\/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy","volume":"8","author":"Arai","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.042_bib0021","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2015-04-642652","article-title":"Efficiency of high-dose cytarabine added to CY\/TBI in cord blood transplantation for myeloid malignancy","volume":"126","author":"Arai","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2026.03.042_bib0022","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.3324\/haematol.2024.285002","article-title":"Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors","volume":"109","author":"Atsuta","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.042_bib0023","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2025.2509353","article-title":"Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed\/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutation","volume":"30","author":"Liang","year":"2025","journal-title":"Hematology"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.042_bib0024","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3109\/07357907.2014.919301","article-title":"Complications of allogeneic hematopoietic stem cell transplantation","volume":"32","author":"Arnaout","year":"2014","journal-title":"Cancer Invest"},{"issue":"5","key":"10.1016\/j.jtct.2026.03.042_bib0025","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/bloodadvances.2022008991","article-title":"Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R\/R FLT3mut AML","volume":"7","author":"Terao","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.03.042_bib0026","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.toxlet.2025.06.018","article-title":"Autophagy-dependent hepatocyte apoptosis mediates gilteritinib-induced hepatotoxicity","volume":"410","author":"Cao","year":"2025","journal-title":"Toxicol Lett"},{"issue":"2","key":"10.1016\/j.jtct.2026.03.042_bib0027","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12185-023-03596-w","article-title":"Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS","volume":"118","author":"Najima","year":"2023","journal-title":"Int J Hematol"},{"issue":"19","key":"10.1016\/j.jtct.2026.03.042_bib0028","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.042_bib0029","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/leu.2017.113","article-title":"Measurable residual disease testing in acute myeloid leukaemia","volume":"31","author":"Hourigan","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jtct.2026.03.042_bib0030","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.03.042_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.12.002","volume":"30","author":"Konuma","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.042_bib0032","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70061","article-title":"Efficacy of total-body irradiation-based intensified myeloablative regimens for acute leukemia-an international collaborative study","volume":"6","author":"Arai","year":"2025","journal-title":"EJHaem"},{"key":"10.1016\/j.jtct.2026.03.042_bib0033","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/10428194.2017.1357173","article-title":"Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients","volume":"59","author":"Yanada","year":"2018","journal-title":"Leuk Lymphoma"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:43:52Z","timestamp":1786088632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726002599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666636726002599"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.042","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance Treatment With Gilteritinib Suppresses Post-transplant Relapse in Relapse\/Refractory FLT3-Mutated Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}